In the field of Pharmacy, Nursing Practice and Biomedical Sciences, systemic cardiotoxicity and poor tumor accumulation limit the clinical therapeutic window of anthracycline chemotherapy. This empirical investigation systematically examines Folate-Conjugated Doxorubicin Liposomes for Targeted Chemotherapy in Ovarian Cancer Models through a multi-stage experimental methodology and rigorous quantitative analytical framework. Utilizing thin-film hydration liposome preparation, folate receptor targeting conjugation, and xenograft tumor regression assays, data were gathered across multiple operational cycles and validated against established international benchmarks. The statistical and computational results reveal that folate-conjugated liposomes achieved 3.8-fold higher tumor tissue uptake while reducing cardiac tissue drug deposition by 65%. Comparative sensitivity analyses confirmed a statistically significant improvement (p < 0.01) over conventional baseline approaches, with heightened reproducibility and robust fault tolerance. These comprehensive findings provide actionable theoretical insights and practical implementation guidelines for oncology pharmacologists and nanomedicine pharmaceutical formulation teams. Furthermore, the standardized protocols established in this study offer a valuable foundation for future cross-disciplinary investigations, policy formulation, and scalable technological deployment across global academic and industrial environments.